Huang, David B.Duncan, Leonard R.Flamm, Robert K.Dryden, MatthewCorey, G. RalphWilcox, Mark H.Torres Martí, AntoniFile, Thomas M.2019-04-122019-04-122018-010732-8893https://hdl.handle.net/2445/132145The in vitro antimicrobial activity of iclaprim, a novel diaminopyrimidine, against common respiratory bacteria remained unchanged in the presence of pulmonary surfactant (Survanta®) at concentrations that greatly antagonized the antimicrobial activity of daptomycin. These results indicate that iclaprim could be a potential treatment for pneumonia caused by susceptible and multidrug resistant bacteria.3 p.application/pdfengcc-by-nc-nd (c) Elsevier B.V., 2018http://creativecommons.org/licenses/by-nc-nd/3.0/esPneumòniaBacteris patògensEfecte dels medicaments sobre els microorganismesPneumoniaPathogenic bacteriaEffect of drugs on microorganismsThe effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogensinfo:eu-repo/semantics/article6751272019-04-12info:eu-repo/semantics/openAccess